Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.

Area of Science:

• Microbiology
• Molecular Biology
• Biotechnology

Background:

• Conventional antibiotics lack specificity, targeting conserved bacterial pathways and affecting beneficial microbes alongside pathogens.
• The need for targeted antimicrobial strategies to combat specific bacterial strains and resistance mechanisms is critical.

Purpose of the Study:

• To develop programmable, sequence-specific antimicrobials utilizing the CRISPR-Cas9 system.
• To demonstrate the ability of these antimicrobials to selectively eliminate virulent bacteria and target antibiotic resistance genes.

Main Methods:

• Reprogramming the RNA-guided nuclease Cas9 to target specific bacterial genes (virulence or antibiotic resistance).
• Delivering the Cas9 system via bacteriophages for targeted action.
• Testing the efficacy of CRISPR-Cas9 antimicrobials in vitro and in vivo using a mouse skin colonization model.

Main Results:

• Cas9-based antimicrobials selectively killed virulent Staphylococcus aureus strains while sparing avirulent ones.
• Reprogrammed Cas9 effectively destroyed staphylococcal plasmids carrying antibiotic resistance genes.
• The technology prevented the spread of plasmid-borne resistance genes by immunizing avirulent staphylococci.
• CRISPR-Cas9 antimicrobials demonstrated efficacy in vivo in a mouse model.

Conclusions:

• CRISPR-Cas9 technology enables the development of programmable, sequence-specific antimicrobials.
• This approach allows for the selective elimination of pathogenic bacteria and the disruption of antibiotic resistance mechanisms.
• The findings present a novel strategy for manipulating complex bacterial populations and combating antimicrobial resistance.